期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

不同肺癌细胞株中VEGFR-2 mRNA表达的实验研究 被引量：3

The expressions of VEGFR-2 mRNA in different lung cancer cell lines
下载PDF
导出
摘要 目的研究不同非小细胞肺癌(NSCLC)细胞株中血管内皮生长因子受体-2(VEGFR-2)mRNA的表达情况。方法采用实时荧光定量PCR法检测人肺黏液表皮样癌NCI-H292细胞株、人肺腺癌NCI-H1299细胞株、人肺腺癌A549细胞株、人肺巨细胞癌95D细胞株和人肺鳞癌Calu-1细胞株中VEGFR-2 mRNA的表达。结果 Calu-1、NCI-H292、95D、NCI-H1299和A549细胞株中VEGFR-2 mRNA表达依次为1.213±0.134、1.008±0.164、0.754±0.088、0.582±0.171和0.121±0.026,差异有统计学意义(F=31.875,P=0.000)。Calu-1与NCI-H292细胞株间VEGFR-2 mRNA表达无统计学差异(P=0.080),NCI-H1299与95D细胞株间VEGFR-2 mRNA表达亦无统计学差异(P=0.137),其余细胞株间差异均有统计学意义(P均<0.05)。结论不同NSCLC细胞株中VEGFR-2 mRNA表达量不同,可能与不同肿瘤细胞的生物学行为有关。 Objective To investigate the expressions of vascular endothelial growth factor receptor 2 （VEGFR-2） mRNA in different lung cancer cell lines.Methods The expressions of VEGFR-2 mRNA in the human pulmonary mucoepidermoid carcinoma cell line NCI-H292,lung adenocarcinoma cell line NCI-H1299,lung adenocarcinoma cell line A549,lung giant cell carcinoma 95D and lung squamous carcinoma cell line Calu-1 were detected by real-time quantitative PCR （RT-PCR）.Results The expressions of VEGFR-2 mRNA were 1.213 ± 0.134,1.008 ±0.164,0.754 ±0.088,0.582 ±-0.171 and 0.121 ±0.026 in Calu-1,NCI-H292,95D,NCI-H1299 and A549 cell lines,showing significant differences （F =31.875,P =0.000）.No significant difference was observed in the expression of VEGFR-2 mRNA between Calu-1 and NCI-H292 （P =0.080） or between NCI-H1299 and 95D （P =0.137）.Conclusion The expression of VEGFR-2 mRNA is diverse in different lung cancer cell lines,which is closed with the different biological behavior.
作者 张莹 蒋晓东 乔云 刘毅 刘亮 丁曼华
机构地区 解放军第 连云港市第一人民医院肿瘤科
出处 《临床肿瘤学杂志》 CAS 2013年第10期879-881,共3页 Chinese Clinical Oncology
基金 国家自然科学基金资助项目(81272558) 卫生部科研基金资助项目(W201210) 江苏省自然科学基金资助项目(BK2012661) 中华国际医学交流基金会资助项目(CIMF-F-H001-250)
关键词 血管内皮生长因子受体2 非小细胞肺癌 MRNA Vascular endothelial growth factor receptor 2 （VEGF-2） Non-small cell lung cancer mRNA
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1Gridelli C,Rossi A,Maione P.New antiangiogenetic agents and non-small cell lung cancer[J].Crit Rev Oncol Hematol,2006,60(1):76-86.
  • 2Ferrara N,Gerber HP,LeCouter J.The biology of VEGF and its receptors[J].Nat Med,2003,9(6):669-676.
  • 3Donnem T,Al-Shibli K,Andersen S,et al.Combination of low vascular endothelial growth factor A(VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with non small cell lung cancer[J].Cancer,2010,116(18):4318-4325.
  • 4Ghosh S,Sullivan CA,Zerkowski MP,et al.High levels of vascular endothelial growth factor and its receptors(VEFR-1,VEGFR-2,neuropilin-1) are associated with worse outcome in breast cancer[J].Hum Pathol,2008,39(12):1835-1843.
  • 5Ling Y,Yang Y,Lu N,et al.Endostar,a novel recombinant human endostatin,exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells[J].Biochem Biophys Res Commun,2007,361(l):79-84.
  • 6Seto H,Higashiyama M,Funai H,et al.Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage 1 non-small-cell lung cancer[J].Lung Cancer,2006,53(1):91-96.
  • 7储节胜,徐建明,张博,葛飞娇,刘烈军,赵传华,王岩,林莉,付亚丽,汪俊.VEGFR-2、PDGFR-β和c-MET在肝细胞癌中的表达及预后分析[J].临床肿瘤学杂志,2012,17(7):609-615. 被引量：6
  • 8蒋晓东,戴鹏,宋大安,吴瑾,黎世秋.HIF-1α、VEGF、VEGFR2在非小细胞肺癌组织中的表达及临床意义[J].临床肺科杂志,2011,16(3):386-388. 被引量：62
  • 9Yang F,Tang X,Riquelme E,et al.Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy[J].Cancer Res,2011,71 (16):5512-552 1.

二级参考文献22

  • 1Lerma E,Romero M,Gallardo A,et al.Prognostic significance of the Fas-recep tor/Fas-ligand system in cervical squamous cell carci-noma[J].Virchows Arch,2005,2(1):211 -22.
  • 2Tee YT,Han CP,Ko JL,et al.Evaluation of matrix metallop rotein-ase-2 expression in cervical carcinogenesis using tissue array and in-tegrated optical density for immunoreactivity[J] Rep rod Sci,2007,14(7):719-26.
  • 3Mizukami Y,Li J,Zhang X,et al.Hypoxia-inducible factor-1 inde-pendent regulation of vascular endothelial growth factor by hypoxia in colon cancer[J].Cancer Res,2004,64(5):1765 -72.
  • 4Bos R,van der Groep P,Greijer AE,et al.Levels of hypoxia-induc-ible factor-1 alpha independently predict prognosis in patients with lymph node negative breast carcinoma[J].Cancer,2003,97 (6):1573-81.
  • 5Buchler P,Reber HA,Buchler M,et al.Hypoxia-inducible factor-1 regulates vascular endothelial growth factor expression in human panereatic cancer[J].Pancreas,2003,26(1):56-64.
  • 6Lee C H,Lee M K,Kang C D,et al.Differential expression of hypox-ia inducible factor 1 alpha and tunor cell proliferation between squa-mous cell carcinomas and adenocarcinomas among operable non-small cell lung carcinomas[J].J Korean Med Sci,2003,18(2):196 -203.
  • 7Buchler P,Reber H A,Buchler M,et al.Hypoxia inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer[J].Pancreas,2003,26(1):56 -64.
  • 8Huynh H, Soo KC, Chow PK, et al. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244(ARRY-142886) in the treatment of hepatocellular car-cinoma[ J]. Mol Cancer Ther, 2007, 6(1) : 138 - 146.
  • 9LIovet JM, Bruix J, Gores GJ. Surgical resection versus transplan- tation for early hepatoce-llularcarcinoma: Clues for the best strat- egy[ J ]. Hepatology, 2000, 31 (4) : 899 - 906.
  • 10Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients [ J ]. J Clin Oncol, 2001,19 (4) :1207 - 1225.

共引文献66

同被引文献35

  • 1Hanahan D,Weinberg RA. Hallmarks of cancer:the next genera- tion[J]. Ce11,2011,144(5) :646-674.
  • 2Soker S, Fidder H, Neufeld G, et al. Characterization of novel vascular endothelial growth factor(VEGF)receptors on tumor ceils that bind VEGF165 via its exon 7-encoded domain[J]. J Biol Chem, 1996,271 (10) :5761-5767.
  • 3Tang X, Kadara H, Behrens C, et al. Abnormalities of the TITF-1 Lineage-Specific Oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis[J]. Clin Cancer Res, 2011,17 (8) : 2434- 2443.
  • 4De Fazio S,Russo E, Ammendola M, et al. Efficacy and safety of bevacizumab in glioblastomas[J]. Curr Med Chem, 2012,19 (7) : 972-981.
  • 5Carrillo de Santa Pau E,Arias FC,Caso Peldez E,et al. Prognos- tic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in pa tients with nonsmall cell lung cancer[J]. Cancer,2009,115(8) : 1701-1712.
  • 6Donnem T, A1-Shibli K, Andersen S, et al. Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and in- dependent favorable prognostic factor in patients with nonsmall cell lung cancer[J]. Cancer,2010,116(18) 14318-4325.
  • 7Seto I-t, Hiqashiyama M, Funai H, et al. Prognostic value of ex- pression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage 1 non-small-cell lung cancer[J]. Lung Cancer,2006,53(1) :91-96.
  • 8Yang F, Tang XM, Riquelme E, et al. Increased VEGFR-2 Gene Copy is associated with chemoresistance and shorter survival in patients with Non-Small-Cell lung carcinoma who receive adjuvant chemother- apy[J]. Cancer Res,2011,71(16) :5512-5521.
  • 9Brown LF, Berse B, Jackman RW, et al. Expression of vascular per- meability factor (vascular endothelial growth {actor)and its receptors in breast cancer[J]. Hum Pathol, 1995,26 (1) : 86.
  • 10Alattar M, Omo A, Elsharawy M, et al. Neuropilin-1 expression in squamous cell carcinoma of the oesophagus[J]. Eur J Cardio- thora Sur,2014,45(3) :514-520.

引证文献3

二级引证文献24

临床肿瘤学杂志
2013年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部